Browse All

Current Filters

CLEAR FILTER x

TITLE

Estimating the 10-Year Time-savings Benefits of Lecanemab Treatment

CMT-HI Upper Limb Subscale Scores Respond to Treatment With Govorestat in Patients With CMT-SORD

Benefit Continues to Accumulate When Treatment is Continued Beyond Plaque Clearance – Estimating Accumulating or Maintained Treatment Benefit in the CLARITY AD and TRAILBLAZER-ALZ2 Trials

Long-term Benefit of Lecanemab in Patients with Low Baseline Amyloid: Estimation of Time Saved